机构：[1]Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[2]Central of Reproductive Medicine, Department of Obstetrics and Gynecology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[3]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[4]Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[5]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[6]Institute of Organ Transplantation, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,四川省人民医院[7]Department of Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院
With the goal of harnessing the host's immune system to provide long-lasting remission and cures for various cancers, the advent of immunotherapy revolutionized the cancer therapy field. Among the current immunotherapeutic strategies, immune checkpoint blockades have greatly improved the overall survival rates in certain patient populations. Of note, CTLA4 and PD-1/PD-L1 are two major non-redundant immune checkpoints implicated in promoting cancer immune evasion, and ultimately lead to relapse. Antibodies or inhibitors targeting these two c+heckpoints have achieved some encouraging clinical outcomes. Further, beyond the canonical immune checkpoints, more inhibitory checkpoints have been identified. Herein, we will summarize recent progress in immune checkpoint blockade therapies, with a specific focus on key pre-clinical and clinical results of new immune checkpoint therapies for cancer. Given the crucial roles of immune checkpoint blockade in oncotherapy, drugs targeting checkpoint molecules expressed by both cancer and immune cells are in clinical trials, which will be comprehensively summarized in this review. Taken together, investigating combinatorial therapies targeting immune checkpoints expressed by cancer cells and immune cells will greatly improve immunotherapies that enhance host elimination of tumors.
基金：
National Science Foundation of China [81802504, 81872207]; Sichuan Medical Association [Q19037]; Sichuan Science and Technology Bureau [2019YFS0439, 2020JDJQ0067, 2021YJ0564, 2022YFH0005]; Chengdu Science and Technology Bureau [2021-YF05-00225-SN]
第一作者机构：[1]Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China,
共同第一作者：
通讯作者：
通讯机构：[4]Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,[5]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,[6]Institute of Organ Transplantation, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China,
推荐引用方式(GB/T 7714)：
Yu Lu,Sun Minghan,Zhang Qi,et al.Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy[J].FRONTIERS IN IMMUNOLOGY.2022,13:doi:10.3389/fimmu.2022.982026.
APA：
Yu, Lu,Sun, Minghan,Zhang, Qi,Zhou, Qiao&Wang, Yi.(2022).Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.FRONTIERS IN IMMUNOLOGY,13,
MLA：
Yu, Lu,et al."Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy".FRONTIERS IN IMMUNOLOGY 13.(2022)
医学